← Leaderboards
Eric M. Poeschla
Va Eastern Colorado Health Care System
$16,873,809
Attributed
$16,873,809
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,873,809 · 7
VA$0 · 1
By mechanism
R01$12,413,166 · 4
DP1$3,887,500 · 1
R21$292,000 · 1
P30$281,143 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1CellsBaseProteinsVirusViralInterestEvolutionLaboratoriesGeneticSubfamily LentivirinaeBiologyResearch StudyPatternGenesFeline Immunodeficiency VirusImmuneResponseResearch PersonnelComplexNatural ImmunityNucleic AcidsCell NucleusFelis Catus
Grant awards (44)
SARS-CoV-2 and Innate Immunity: Mechanisms of Resistance to Human Interferons$0
I01 · FY2025 · VA · contact PI
SARS-CoV-2 and Innate Immunity: Mechanisms of Resistance to Human Interferons$0
I01 · FY2024 · VA · contact PI
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses$777,500
DP1 · FY2021 · DA · contact PI
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses$777,500
DP1 · FY2020 · DA · contact PI
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses$777,500
DP1 · FY2019 · DA · contact PI
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses$777,500
DP1 · FY2018 · DA · contact PI
Dependency Factors in HIV-1 Cytoplasmic-Nuclear Transit and Intgeration$463,511
R01 · FY2018 · AI · contact PI
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses$777,500
DP1 · FY2017 · DA · contact PI
Dependency Factors in HIV-1 Cytoplasmic-Nuclear Transit and Intgeration$463,511
R01 · FY2017 · AI · contact PI
Introducing restriction factors into the genome of an AIDS virus host species$617,008
R01 · FY2016 · AI · contact PI
Dependency Factors in HIV-1 Cytoplasmic-Nuclear Transit and Intgeration$463,511
R01 · FY2016 · AI · contact PI
Introducing restriction factors into the genome of an AIDS virus host species$686,962
R01 · FY2015 · AI · contact PI
Dependency Factors in HIV-1 Cytoplasmic-Nuclear Transit and Intgeration$463,014
R01 · FY2015 · AI · contact PI
Introducing restriction factors into the genome of an AIDS virus host species$666,848
R01 · FY2014 · AI · contact PI
Dependency Factors in HIV-1 Cytoplasmic-Nuclear Transit and Integration$473,944
R01 · FY2014 · AI · contact PI
Introducing restriction factors into the genome of an AIDS virus host species$570,511
R01 · FY2013 · AI · contact PI
Introducing restriction factors into the genome of an AIDS virus host species$594,943
R01 · FY2012 · AI · contact PI
LEDGF/p7 and HIV Integration$377,170
R01 · FY2012 · AI · contact PI
LEDGF/p7 and HIV Integration$7,846
R01 · FY2012 · AI · contact PI
Eicosanoid Gene Therapy$359,014
R01 · FY2011 · EY · contact PI
LEDGF/p7 and HIV Integration$344,259
R01 · FY2011 · AI · contact PI
Eicosanoid Gene Therapy$373,973
R01 · FY2010 · EY · contact PI
LEDGF/p7 and HIV Integration$336,575
R01 · FY2010 · AI · contact PI
LEDGF/p7 and HIV Integration$33,481
R01 · FY2010 · AI · contact PI
Eicosanoid Gene Therapy$377,750
R01 · FY2009 · EY · contact PI
LEDGF/p7 and HIV Integration$339,975
R01 · FY2009 · AI · contact PI
Eicosanoid Gene Therapy$377,750
R01 · FY2008 · EY · contact PI
LEDGF/p7 and HIV Integration$339,975
R01 · FY2008 · AI · contact PI
Lentiviral Genome Processing$277,189
R01 · FY2008 · AI · contact PI
Lentiviral Transgenesis of the Aqueous Outflow Tract$366,180
R01 · FY2007 · EY · contact PI
Lentiviral Genome Processing$282,558
R01 · FY2007 · AI · contact PI
Lentiviral Transgenesis of the Aqueous Outflow Tract$402,322
R01 · FY2006 · EY · contact PI
Lentiviral Genome Processing$290,997
R01 · FY2006 · AI · contact PI
Lentiviral Transgenesis of the Aqueous Outflow Tract$365,000
R01 · FY2005 · EY
Lentiviral Genome Processing$253,300
R01 · FY2005 · AI
Lentiviral Transgenesis of the Aqueous Outflow Tract$33,911
R01 · FY2005 · EY
Lentiviral Transgenesis of the Aqueous Outflow Tract$365,000
R01 · FY2004 · EY
Lentiviral Transgenesis of the Aqueous Outflow Tract$365,000
R01 · FY2003 · EY
Lentiviral Genome Processing$292,000
R21 · FY2003 · AI
NOVEL LENTIVIRAL VECTORS FOR SUSTAINED GENE EXPRESSION$233,461
R01 · FY2002 · AI
NOVEL LENTIVIRAL VECTORS FOR SUSTAINED GENE EXPRESSION$226,659
R01 · FY2001 · AI
CORE--GENE THERAPY$180,480
P30 · FY2001 · AI
NOVEL LENTIVIRAL VECTORS FOR SUSTAINED GENE EXPRESSION$220,058
R01 · FY2000 · AI
CORE--GENE THERAPY$100,663
P30 · FY2000 · AI